The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
The company is bringing precision therapies for gynaecological cancers
The company has improved access to quality healthcare for seniors across both urban and rural areas
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
The facility will be positioned as a Centre of Excellence for tertiary care services
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Subscribe To Our Newsletter & Stay Updated
